Endocrine therapy is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer. However, resistance to hormone therapies frequently occurs during the course of treatment. Growing understanding of the signal cascade of estrogen receptors and the signaling pathways that interact with estrogen receptors has revealed the complex role of these receptors in cell growth and proliferation, and on the mechanism in development of resistance. These insights have led to the development of targeted therapies that may prove to be effective options for the treatment of breast cancer and may overcome hormone therapy resistance. This article reviews current understanding of the cellular receptor signaling pathways that interact with estrogen receptors. It also reviews data from recent ongoing clinical trials that examine the effects of targeted therapies, which might interfere with estrogen receptor pathways and might reduce or reverse resistance to traditional, sequential, single-agent endocrine therapy.
Introduction
Breast cancer is the most common malignancy and the second leading cause of cancer-related death among women in the United States according to 2016 estimates. 1 Approximately 6% of cases are advanced or metastatic breast cancer (MBC) at diagnosis, and, for those diagnosed at early stages, recurrence to distant sites occurs in 20% to 30%. [2] [3] [4] Of patients with breast cancer, approximately 75%
have hormone receptor-positive (HR þ ) tumors. 5 Therapies for MBC are aimed at palliation of symptoms with improvement or conservation of quality of life and, potentially, prolongation of survival; unfortunately, prolonged survival is observed in only a small percentage of patients. 6, 7 Both hormone receptor status (eg, estrogen receptor [ER] and progesterone receptor [PgR] ) and human epidermal growth factor 2 (HER2) status are important predictive markers for treatment efficacy. 7, 8 Patients with HR þ MBC are candidates for initial endocrine therapy (ET). 9 In premenopausal women with MBC, various endocrine treatments are employed, including ovarian suppression or oophorectomy, selective ER modulators such as tamoxifen, aromatase inhibitors (AIs) in conjunction with ovarian suppression, and the selective ER downregulator, fulvestrant, all of which have different mechanisms of action. These mechanisms have been reviewed extensively, demonstrating the diversity of approaches that ultimately antagonize the growthpromoting effects of estrogen on breast cancer cells. These mechanistic differences are also linked to dissimilarities in resistance mechanisms and thus influence treatment selection, particularly in the context of sequencing and the use of combination regimens. [10] [11] [12] [13] [14] [15] [16] [17] In the setting of postmenopausal HR þ MBC, ET has a better tolerability profile and longer time to progression (TTP) than chemotherapy. 18, 19 In clinical trials of AIs employed for first-or second-line treatment of postmenopausal patients with MBC, AIs have greater efficacy than either tamoxifen or megestrol acetate. 20 Resistance to ET in HR þ MBC is common, and given sufficient time, most patients are faced with disease progression. 21, 22 The mechanisms underlying disease progression and the development of resistance to endocrine treatment are complex and not fully understood. Nevertheless, over the past several years, insights into several pathways of resistance have grown and have led to increased understanding of the clinical value of sequential lines of therapy and co-targeting strategies. While receiving ET, up to 20% of patients experience a loss of ERs with concomitant loss of response to estrogen. 23 Amplified expression of HER2 may reduce ER levels and serve as an alternative pathway for tumor cell survival. 23, 24 Cellular signaling of growth-factor receptors interacts with ER nuclear and nonnuclear pathways and may contribute to resistance through posttranslational modifications of ER and/or coregulators. [25] [26] [27] Mutations and/or aberrant forms of ER and their coregulators may also be a primary cause or contribute to the development of resistance to ET. 21, 22, 25 The aim of this review is to describe emerging information on cellular pathways that interact with ER and impact cell proliferation and development of resistance to ET. We will discuss the biologic rationale for combining ET with agents that target these pathways and review the current status of clinical trials that are investigating the effects of combination treatments (Table 1) . We also illustrate the cellular receptors and intracellular signaling pathways that interact with ER ( Figure 1 ).
Estrogen-Receptor Signaling
ER functions through 2 separate but interrelated pathways: nuclear (genomic) and nonnuclear (nongenomic) pathways. The nuclear pathway mediates the effects of ER on genomic activity, thereby altering expression of many genes involved in physiologic cell function and in abnormal cell proliferation, resulting in tumorigenesis. 28 The ER nuclear pathway is activated by estrogen binding, receptor dimerization and translocation to the nucleus, interaction with coregulator proteins (both coactivators and corepressors), and through estrogen response elements modulation of gene transcription. 29 ER coregulators have been implicated in the pathogenesis of breast cancer. Most notable is amplified in breast cancer 1, which, as its name implies, is overexpressed in breast cancers. Moreover, amplified in breast cancer 1 overexpression may play a role in resistance to ET. 30 The nonnuclear pathway of ER function (originating in cellular cytoplasm) is mediated by estrogenbound ER acting outside the cell nucleus through interaction with multiple cellular signaling pathways, tyrosine kinases, and membrane-bound growth factor-receptor pathways, including HER2, insulin-like growth factor-1 receptor (IGF1R), and fibroblast growth factor receptor (FGFR). 31, 32 Multiple levels of interaction or crosstalk between ER and growth factor and tyrosine kinase pathways may contribute to ER actions. These interactions include modulation of ER activity, upregulation of competing pathways and development of resistance to ET, and alternative or escape pathways for cellular proliferation and tumorigenesis. Estrogen can modify the activity of growth factor pathways by increasing levels of growth factors such as transforming growth factor-a and IGF1R and, alternatively, by altering the expression of epidermal growth factor receptors (EGFR). 27, 32, 33 Conversely, activation of growth factor-receptor signaling pathways may downregulate expression of ER, resulting in decreased estrogen effects. 34, 35 This crosstalk, which can up-or downregulate competing pathways between ER and growth factor-receptor signaling, is recognized as a major mechanism of ET resistance, and implies that ER-positive (ER þ )/HER2-positive (HER2 þ ) breast cancer should be treated with a combination of ET and HER2 inhibitors or antagonists. 36 In addition to ER and HER2 status, assessment of PgR status is also typically used to characterize MBC and shape treatment decisions. In normal breast tissue, ER and PgR appear to be expressed in different epithelial populations and regulate distinct pathways; estrogen is involved in extracellular signaling and progesterone is associated with cell growth. 8 This independent activity is altered in breast cancer cells where ER and PgR expression become correlated and converge on pathways that promote tumor growth and metastasis, and both PgR and ER become regulated by estrogen. 8 Although PgR in ER þ patients with MBC has been used as a predictor of response to ET, it is controversial and not as well-accepted as the role of ER. 37 Data indicate that ER þ /PgR-negative (PgR À ) breast tumors are not as responsive to selective ER modulator therapy as ER þ /PgRpositive (PgR þ ) tumors. One proposed mechanism for this antiestrogen resistance involves aberrant growth factor signaling (a marker for loss of PgR), but other unknown contributory mechanisms are also likely to play a role. Further research is needed to identify such mechanisms and thereby refine therapeutic strategies. 38 In a recent study of MBC, PgR was found to associate with ER in the presence of agonist ligands, and the ER-PgR ligand-activated complex acted to modify chromatin-binding events and gene transcription, leading to an antitumorigenic effect. 39 Stimulation with progesterone in an estrogen-rich context induced interactions between known ER cofactors and PgR, but did not alter the association of those cofactors with ER, yielding an ER-PgR binding complex that promoted cell death, apoptosis, and differentiation pathways. 39 This finding, coupled with the association between PgR gene (PgR) copy number loss and poorer clinical outcome possibly owing to a reduction in ER-PgR binding complex formation, suggests a more intricate relationship beyond PgR as a simple marker for ER pathway function in the MBC setting. 39 Although this contrasts with hormone replacement studies in which synthetic progesterone (medroxyprogesterone) was associated with an increased breast cancer risk, it was found that natural progesterone did not have the same effect, which suggests different mechanisms of action for synthetic agonists. 40 43 Among the Luminal B patients, pathologic complete response was 85%, suggesting a possible association between ER/PgR status and the benefit of chemotherapy. 43 Clearly the complex relationship between ER and PgR depends on many factors, including genomic alteration, interaction of cofactors at a transcriptional level, relative levels of estrogen and progesterone in the tumor cell environment, and possibly variations in conformational changes related to the form of the agonist.
Growth-Factor Receptors
Growth-factor receptors, particularly receptor tyrosine kinases, play an integral role in growth promotion, cellular proliferation, and tumorigenesis. Growth-factor pathways may act as ER-independent drivers of tumor growth and survival, contributing to resistance to
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Alternate Pathways on Estrogen Receptor in Metastatic Breast Cancer all types of ET. HER2, IGF1R, and FGFR have been implicated in resistance. 26, 44, 45 In breast cancer, HER2, a member of the EGFR family, is an important independent pathway for cell proliferation. 46 HER2 is constitutively in an active conformation that allows dimerization with itself (homodimerization) or other members of the EGFR family (heterodimerization). When HER2 is overexpressed, as it is in w15% to 20% of all breast cancers, it mediates cell growth and survival through activation of its downstream mediators, PI3K/Akt/mTOR and Ras/Raf/MEK/MAP kinase. 47 Overexpression of HER2 (HER2 þ ) is an independent prognostic (and predictive for sensitivity to its antagonists/inhibitors) factor indicating a more aggressive form of cancer with a higher recurrence rate and higher mortality. with inhibitors of other pathways may prove more effective. Growth factor receptor pathways such as HER2, IGF1R, and FGFR, which are independent of ER signaling, can subvert ET and lead to tumor cell growth and proliferation in MBC. Combination strategies, which include monoclonal antibodies that block growth factor receptors, coupled with tyrosine kinase inhibitors or other agents that act to disrupt signaling of multiple downstream effector molecules may be an effective approach to optimize treatment for the patient with MBC.
Alternate Pathways on Estrogen Receptor in Metastatic Breast Cancer

Intracellular Signaling Cascades
PI3K/Akt/mTOR Pathway. The PI3K signaling pathway plays a vital role in cell proliferation, differentiation, and cell survival. 70 The cell cycle is often dysregulated in cancer cells, resulting in reduced growth-factor dependency and increased replicative potential. Approximately 8% of breast cancers have mutations in PI3K; gainof-function mutations in the PI3K alpha catalytic subunit (PIK3CA) occur in approximately 30% of ER þ breast cancers and are a common genomic alteration in this subtype of breast cancer. 71, 72 PI3K is activated by growth-factor receptor tyrosine kinases, HER2, EGFR, IGF1R, and FGFR, and through a series of steps, activation of PI3K stimulates the downstream mediators Akt and mTOR. 73 The PI3K pathway interacts with ER directly and indirectly in that PI3K and Akt can phosphorylate and thereby activate ER in the absence of estrogen. 74, 75 This interaction of the PI3K pathway with ER confers ET resistance. 74, 76 A phase II clinical trial that studied the combination of ET with everolimus, an inhibitor of mTOR, tested the rationale that inhibition of the PI3K pathway might amplify response or reverse resistance to ET. In patients with HR þ breast cancer, the combination of everolimus and letrozole resulted in increased clinical response and suppression of tumor cell proliferation compared with letrozole and placebo. 77 The Tamoxifen Plus Everolimus (TAMRAD) study in patients with HR þ HER2 À MBC who had progressed on an AI found that the addition of everolimus to tamoxifen improved clinical benefit rate, TTP, and OS compared with tamoxifen alone. 78 The phase III Combination of everolimus with trastuzumab plus paclitaxel as fi rst-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-2) trial showed that treatment with everolimus plus exemestane demonstrated a median TTP of 10.6 months compared with 4.1 months with exemestane alone in postmenopausal HR þ MBC that recurred or progressed on previous ET. 79, 80 However, in the phase III Placebo-controlled trial of letrozole plus oral temsirolimus (HORIZON) trial, the addition of 
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Clinical Breast Cancer April 2017 -85 the mTOR inhibitor temsirolimus to letrozole did not lead to improvement in PFS in AI-naive advanced breast cancer. 81 Several differences between these trials may contribute to the varied results. First, patient populations differed, with AI-resistant patients in the TAMRAD and BOLERO-2 trials, but AI-naive patients in the HORIZON trial. With both mTOR inhibitors subject to metabolism by the same CYP enzyme (CYP3A), population differences in its expression might have resulted in variable metabolism across diverse ethnic groups. Genotypic and phenotypic variation across populations may have also accounted for variable response. Finally, relative differences in drug effectiveness between everolimus and temsirolimus cannot be ruled out. 82 Ongoing studies of fulvestrant with everolimus and standard ET with everolimus will provide additional perspective on the potential combined benefit of mTOR and ER inhibition (NCT01797120, NCT02035813). Inhibitors of PI3K in preclinical and clinical trials for breast cancer include BKM120, LY294002, GDC0941, BYL719, and GDC0032. 83 Additionally, combination PI3K/mTOR inhibitors, GDC0980 and BEZ235, are also being studied. In preclinical studies, GDC0980, GDC0032, and GDC0941, given in combination, enhanced activity of fulvestrant in MCF-7 xenografts, resulting in tumor regression and tumor growth delay. 84 A combination of tamoxifen, everolimus, and LY294002 produced increased antitumor effects compared with tamoxifen alone or tamoxifen and everolimus in a breast cancer cell line. 85 In addition, treating breast cancer cells with BEZ235 induced apoptosis when combined with estrogen deprivation, suggesting potential activity in HR þ breast cancer. 86 In an initial phase I/II study, patients with trastuzumab-resistant locally advanced or metastatic HER2 þ breast cancer were treated with BKM120 (buparlisib) and trastuzumab. Two patients (17%) had partial responses, and 7 (58%) had stable disease (! 6 weeks) with a disease-control rate of 75%. 87 Buparlisib in combination with letrozole has also been used to treat ER þ HER2 À MBC, and provided clinical benefit in both patients with PI3K-wild type and mutant tumors, but patients with coexisting PI3K and MAP3K mutations derived the greatest clinical benefit from this regimen. 88 The Akt inhibitor MK2206 is also being studied in breast cancer. In MCF-7 cells, overexpression of constitutively active Akt1 induced resistance to anastrozole; addition of the Akt inhibitor MK2206 restored sensitivity to this AI. 89 Taken together, the preclinical and clinical data suggest that ER and PI3K pathways counter-regulate each other with low PI3K activation resulting in high ER levels, and hyperactivation of PI3K causing a reduction in ER levels. 90 Further validation of this notion comes from studies showing that inhibition of HER2 with the antibody trastuzumab or the tyrosine kinase inhibitor lapatinib restores or upregulates ER levels or transcriptional activity in breast cancer cells and patient tumors. 91, 92 Also, AIs or fulvestrant inhibit the growth of HER2 þ tumors that have progressed on trastuzumab or lapatinib. 92 Numerous ongoing phase I to III studies are examining the effects of AIs or fulvestrant in combination with PI3K and Akt inhibitors (NCT01610284, NCT01633060, NCT01791478, NCT02088684, NCT01248494, NCT01339442, NCT01437566, NCT01296555, and NCT01344031). Src kinases, intracellular tyrosine kinases that contribute to control of cell proliferation, have been implicated in oncogenic activity in breast cancer, particularly HR þ breast cancer. 93 Dasatinib is a small-molecule inhibitor of several Src family kinases approved for use in chronic myelogenous leukemia. 94 A recent phase II trial of dasatinib in women with MBC showed modest activity with disease control rates (ie, complete response, partial response, or stable disease for at least 16 weeks) for 8.3% of patients with HER2 þ MBC and 15.6% of those with HR þ MBC. 95 Early results of a trial of dasatinib in combination with fulvestrant as second-line treatment of HR þ MBC in postmenopausal women did not find improved efficacy with the addition of dasatinib. 96 With the variety of agents available that target the PI3K/Akt/ mTOR pathway, the challenge remains to identify which subset of targets, and therefore, which combination of agents may be the most impactful to maximize clinical benefit and adapt to ET resistance in individual patients.
Cell Cycle Control and Proliferation
Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET and that treat HR þ MBC. Cyclin-dependent kinases (CDKs) are a subgroup of serine/threonine kinases that play a key role in regulating cell cycle progression. 97 The cell cycle G1 to S-phase transit is controlled by CDK4 and CDK6, which are activated upon binding to D-type cyclins leading to expression of genes required for S-phase entry. 98 Several studies have identified alterations of cell cycle regulators in human breast cancer and provide a rationale for the potential therapeutic role for CDK4/6 inhibition in breast tumors. Cyclin D1 is a direct transcriptional target of ER. 99 112 This agent is also being examined in combination with fulvestrant and PI3K inhibitors (NCT02088684). The CDK pathway regulates the cell cycle, with CDK4 and 6 directly controlling the gap phase 1 of mitosis (G1). Dysregulation of these components may occur through multiple mechanisms contributing to tumor growth and metastatic potential, and is a common feature in many cancers, including breast cancer. Therefore, therapeutic inhibition of CDK is a relevant treatment strategy, and a number of agents are currently under investigation in clinical trials. 98, 105 Ongoing clinical trials that combine CDK inhibitors with inhibitors of other dysregulated pathways commonly found in breast cancer may improve outcomes and act to overcome ET resistance.
Immune Response Modulation
Antitumor immunity in human cancer is often ineffective owing to the tight regulation associated with the maintenance of immune homeostasis. Previous attempts to develop effective immunotherapies for cancer have been unsuccessful because there are significant barriers that have been difficult to overcome. However, blockade of the programmed death receptor (PD-1), which may play a role in the tumor's ability to bypass immune modulation and is overexpressed in certain tumors such as melanoma, has been proven effective for treatment. [113] [114] [115] Additionally, a monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune checkpoint molecule that downregulates pathways of T-cell activation, has also been proven effective for treatment of melanoma. 116 The place of PD-1 and CTLA-4 inhibition in the treatment of HR þ MBC is not as clearly defined.
The extent of mutations and aberrant protein expression associated with cancer cells may also dictate the potential for efficacy of immunotherapy. 117 Foreign antigens expressed on the surface of pathogens trigger the body's immune system to target and eliminate these invaders. However, tumor cells are often undetected by immune surveillance owing to identification of tumor cells as "self." Although tumor cells may over express tumor-associated antigens, these same antigens are expressed at low levels on normal cells, leading to immune tolerance. In contrast, neoantigens that arise due to mutations in a tumor cell, which are not expressed on any other normal cells, represent prime targets for Tecell-mediated elimination with no risk to normal tissues. 117 This has led to the hypothesis that tumors with high mutation rates have increased neoepitopes, and use of checkpoint blockade therapies (PD-1, PD-L1, and CTLA-4) can reactivate tumor-infiltrating T cells in these cases, leading to tumor regression. 117 The heterogeneous nature of breast cancer has led to studies that seek to identify biomarkers associated with drug response. Triplenegative breast cancer (TNBC) lacks the molecular targets for many treatment options and is associated with high genetic alteration rates. In particular, one study of 2111 patients with TNBC (ER
À ) found that 91% of patients showed diminished androgen receptor expression and/or mutations in PI3KCA/ PTEN/AKT1, or loss of PTEN. 118 In addition, expression of PD-L1 is more prevalent in TNBC, and this coupled with increased PD-L1-mediated T-cell reactivation suggests that PD-L1 inhibitors may be effective in this patient population. 117, 119 In fact, a preliminary study that targeted PD-L1 showed promising objective clinical activity in TNBC patients (NCT01375842).
119
Estrogen-Receptor Degradation and Proteasome Inhibitors (PIs)
Proteasomes are multicatalytic protease complexes in the cell, involved in the non-lysosomal recycling of intracellular proteins. Proteasomes play a critical role in regulation of cell division in both normal and cancer cells. [120] [121] [122] [123] In cancer cells, this homeostatic function is deregulated, leading to the hyperactivation of the proteasomes. PIs interfere with the ubiquitin proteasome pathway and lead to the accumulation of proteins engaged in cell cycle progression. They ultimately put a halt to cancer cell division and induce apoptosis. Cell cycle proteins are regulatory proteins whose temporal activity is tightly controlled and are thus important targets of proteasome degradation. Major proteins related to the cell cycle process are cyclins, CDKs, CDK inhibitors (CKIs), and some transcription factors. Cyclin proteins are found to be highly upregulated in cases of aberrant cell division in cancer cells, particularly cyclins D and E. 124, 125 The precise mechanism of action of PIs in cancer treatment is not well-understood. In treatment of breast cancer, 2 potential mechanisms have been described: the PI, bortezomib, may inhibit cell proliferation and may decrease levels of ER. 126, 127 Results from early preclinical and clinical trials have been mixed, with 1 small study showing no effect of treatment with bortezomib and another showing enhanced MCF-7 tumor suppression with bortezomib and trastuzumab. 128 Data in MCF-7 breast cancer cells suggest that fulvestrant's antiestrogenic effects of induction of proteasomal degradation of ER may involve c-SRC, a cellular kinase protooncogene. In light of this potential interaction, a phase II study of fulvestrant and bortezomib in women with locally advanced or MBC is underway (NCT01142401).
Epigenetic Modifiers
In addition to genetic alterations such as the mutations and deletions that alter the composition of genomic DNA, epigenetic changes including DNA methylation, histone modifications, and chromatin remodeling can reversibly alter gene expression and play a key role in tumorigenicity and metastatic potential of breast cancer cells. 129 
Therapeutic interventions that target epigenetic modifications have
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Several clinical trials of these epigenetic agents are planned or underway in the breast cancer setting. Azacitidine and decitabine are hypomethylating agents that inhibit DNA methyltransferase, thereby halting tumor cell growth and division through epigenetic manipulation. 130, 131 Both agents have been approved for use in myelodysplastic syndrome and are currently being investigated for breast cancer treatment. 130, 131 In combination with fulvestrant, azacitidine is being evaluated in a phase II trial in patients with ER þ , HER2 À MBC who have progressed on an AI (NCT02374099). In addition, a class I HDAC inhibitor, entinostat, was assessed in a phase II trial (NCT00676663) with or without the AI exemestane in patients with ER þ breast cancer who have progressed on an AI, and the combination was found to not only improve PFS and OS, but restore sensitivity to hormone therapy. 132 Entinostat is currently being studied in combination with azacitidine in a phase II trial of patients with either TNBC or HR þ HER2 À breast cancer (NCT01349959).
Decitabine in combination with the HDAC inhibitor panobinostat (LBH589) was also being investigated in TNBC in an attempt to reexpress ER; however, the study was closed due to slow accrual (NCT01194908).
Conclusions
ER-targeted therapy is important for many women with breast cancer, but resistance to therapy inevitably occurs. The ER signaling pathway is a complex network of extensive crosstalk with growth-factor signaling pathways, cell cycle control pathways, and protein degradation pathways. These pathways provide many alternative targets for agents that may be useful in combination with ET to decrease resistance to treatment and to extend benefit to patients who do not achieve optimal benefit from ET alone. As effective treatments are identified, an important area of focus must be on the factors that determine optimal combination treatments in subtypes of breast cancer. Such factors comprise not only the responsiveness of the cells of a particular subgroup of tumors, but also the characteristics of different treatment combinations with respect to the temporal profile of effects, relative tolerability of different combinations, and the compatibility of routes of administration. Several therapies that are discussed in this review, among them everolimus (mTOR inhibitor), palbociclib (CDK4/6 inhibitor), and MK-3475 (PD-1 inhibitor), are already proving to be effective treatments for MBC and useful in reversing or preventing the development of resistance to ET. Through inhibition of central components of pathways for growth factor-promoted cellular proliferation, cell cycle-mediated cellular proliferation, and immunosuppressive programs that initiate and sustain tumor growth, these agents are effective options that may extend survival and maintain quality of life for women with MBC who have relapsed on endocrine therapies.
